Skip to main content
Fig. 1 | Breast Cancer Research

Fig. 1

From: MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib

Fig. 1

Levels of MCL-1, BCL-XL, BCL-2, BIM, PUMA, NOXA and p53 in breast cancer cell lines, immortalized breast epithelial cell lines and breast carcinoma. (a) Western blot using breast cell lines. Lysates from MCF10A cell lines were loaded in the first lane of each gel as a control for exposure and β-actin was used as a loading control. Data are representative of three independent western blots. (b) Immunohistochemistry using an antibody to MCL-1 in breast carcinoma tissue microarrays showing absent to strong (0–3) cytoplasmic levels. Nuclear staining was also detected in some cases (3). Box and whisker plots depicting the mean Histoscore of (c) cytoplasmic and (d) nuclear MCL-1 staining in basal-like (BL), HER2-positive (HER2), luminal A (LA) and luminal B (LB) breast carcinoma tissue microarrays. (e) Kaplan–Meier survival curve for breast cancer specific survival of luminal A patients with higher cytoplasmic MCL-1 (Histoscore > 100) or lower cytoplasmic MCL-1 (Histoscore > 100). Log-rank p value. HR hazard ratio, MCL-1 myeloid cell leukemia 1 (Color figure online)

Back to article page